Xencor, Inc. (NASDAQ:XNCR) Receives $34.38 Average Price Target from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $34.38.

XNCR has been the topic of a number of analyst reports. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Piper Sandler upgraded Xencor from a "neutral" rating to an "overweight" rating and upped their target price for the company from $20.00 to $30.00 in a research note on Monday, December 2nd.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC lifted its stake in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Xencor in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC lifted its position in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 508 shares in the last quarter. Quarry LP grew its stake in Xencor by 111.4% during the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 2,108 shares during the period. Finally, KBC Group NV increased its position in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 813 shares in the last quarter.

Remove Ads

Xencor Price Performance

Shares of NASDAQ:XNCR traded down $0.28 on Tuesday, hitting $11.23. The company had a trading volume of 848,533 shares, compared to its average volume of 594,746. The company has a market cap of $791.29 million, a PE ratio of -3.51 and a beta of 0.74. The business has a 50 day moving average of $15.72 and a 200 day moving average of $20.14. Xencor has a 52-week low of $10.90 and a 52-week high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.